NO20000762D0 - Anvendelse av substituerte adeninderivater til behandling av multippel sklerose - Google Patents

Anvendelse av substituerte adeninderivater til behandling av multippel sklerose

Info

Publication number
NO20000762D0
NO20000762D0 NO20000762A NO20000762A NO20000762D0 NO 20000762 D0 NO20000762 D0 NO 20000762D0 NO 20000762 A NO20000762 A NO 20000762A NO 20000762 A NO20000762 A NO 20000762A NO 20000762 D0 NO20000762 D0 NO 20000762D0
Authority
NO
Norway
Prior art keywords
multiple sclerosis
treatment
adenine derivatives
substituted adenine
formula
Prior art date
Application number
NO20000762A
Other languages
English (en)
Other versions
NO20000762L (no
NO322328B1 (no
Inventor
Ernest Beutler
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20000762L publication Critical patent/NO20000762L/no
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of NO20000762D0 publication Critical patent/NO20000762D0/no
Publication of NO322328B1 publication Critical patent/NO322328B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20000762A 1992-02-19 2000-02-16 Anvendelse av substituerte adeninderivater til behandling av multippel sklerose NO322328B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/838,546 US5310732A (en) 1986-02-03 1992-02-19 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
PCT/US1993/001467 WO1993016706A1 (en) 1992-02-19 1993-02-18 Use of substituted adenine derivatives for treating multiple sclerosis

Publications (3)

Publication Number Publication Date
NO20000762L NO20000762L (no) 1994-09-13
NO20000762D0 true NO20000762D0 (no) 2000-02-16
NO322328B1 NO322328B1 (no) 2006-09-18

Family

ID=25277387

Family Applications (2)

Application Number Title Priority Date Filing Date
NO942765A NO309025B1 (no) 1992-02-19 1994-07-25 Anvendelse av substituerte adeninderivater for fremstilling av preparater til behandling av multippel sklerose
NO20000762A NO322328B1 (no) 1992-02-19 2000-02-16 Anvendelse av substituerte adeninderivater til behandling av multippel sklerose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO942765A NO309025B1 (no) 1992-02-19 1994-07-25 Anvendelse av substituerte adeninderivater for fremstilling av preparater til behandling av multippel sklerose

Country Status (15)

Country Link
US (4) US5310732A (no)
EP (1) EP0626853B1 (no)
JP (1) JP2688113B2 (no)
AT (1) ATE192045T1 (no)
AU (1) AU682818B2 (no)
BR (1) BR9305907A (no)
CA (1) CA2130275C (no)
CH (1) CH684310A5 (no)
DE (1) DE69328474T2 (no)
DK (1) DK0626853T3 (no)
FI (1) FI943805A (no)
HU (1) HU218656B (no)
NO (2) NO309025B1 (no)
RU (1) RU2130308C1 (no)
WO (1) WO1993016706A1 (no)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5624913A (en) * 1991-04-05 1997-04-29 Wisconsin Alumni Research Foundation Method reducing TNF-alpha in mammals with cerebral malaria
WO1993023058A1 (en) * 1992-05-19 1993-11-25 The Scripps Research Institute Use of 2-halo adenine derivatives as therapeutic agents against chronic myelogenous leukemia
US5424296A (en) * 1993-04-15 1995-06-13 The Scripps Research Institute 2-Halo-2'-deoxyadenosines as therapeutic agents against malignant astrocytoma
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US5773570A (en) * 1994-05-20 1998-06-30 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
US7094597B1 (en) * 1994-05-20 2006-08-22 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
JPH10505323A (ja) * 1994-05-26 1998-05-26 ザ スクリップス リサーチ インスティテュート ２−ハロ−２’−デオキシアデノシンによる炎症性腸疾患の治療
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
US5817641A (en) * 1994-07-21 1998-10-06 Thomas Jefferson University Treatment of enterotoxigenic diarrhea with 2-substituted adenosine derivatives
US5510336A (en) * 1994-09-06 1996-04-23 Saven; Alan 2-halo-2'-deoxyadenosine treatment for histiocytosis
US5641757A (en) * 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
DK0801571T3 (da) * 1994-12-22 2003-01-06 Ortho Pharma Corp Opløselige 2'-chlor-2'-deoxyadenosion-formuleringer
AU762821B2 (en) * 1994-12-22 2003-07-03 Ortho-Mcneil Pharmaceutical, Inc. 'Soluble 2-chloro-2'-deoxyadenosine formulations'
AU706159B2 (en) * 1995-02-10 1999-06-10 Schering Aktiengesellschaft Pharmaceutical preparations for TNF inhibition
US5811073A (en) * 1995-06-19 1998-09-22 President And Fellows Of Harvard College Method for radioisotopic detection and localization of inflammation in a host
US6096310A (en) * 1997-04-15 2000-08-01 Bier; Milan Oral immunotherapy of bacterial overgrowth
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6174873B1 (en) 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
WO2001007054A1 (en) * 1999-07-22 2001-02-01 Supergen, Inc. Methods for treating autoimmune diseases
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
NZ520852A (en) * 2000-02-18 2004-03-26 Southern Res Inst Intermediates and methods for synthesizing 2-chloro-9- (2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine
US6989146B2 (en) * 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
US7608683B2 (en) * 2000-08-09 2009-10-27 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
EP1355923B1 (en) 2000-11-01 2012-03-07 The Regents of The University of California Immunomodulatory peptides derived from heat shock proteins and uses thereof
WO2002078446A1 (en) * 2001-03-29 2002-10-10 Bioenergy Inc. Composition to reduce exercise-induced swelling of joints
US7528247B2 (en) * 2001-08-02 2009-05-05 Genzyme Corporation Process for preparing purine nucleosides
US7368423B1 (en) * 2001-12-05 2008-05-06 The Scripps Research Institute Composition and method for treating chronic allograft rejection
US20060135463A1 (en) * 2002-09-27 2006-06-22 Wood Christopher B Methods and compositions for the treatment of lupus using clofarabine
CA2500360A1 (en) * 2002-09-27 2004-04-08 Bioenvision, Inc. Methods and compositions for the treatment of autoimmune disorders using clofarabine
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
US20080221029A1 (en) * 2002-10-31 2008-09-11 Regents Of The University Of Colorado Methods for treatment of thiol-containing compound deficient conditions
GB0228723D0 (en) * 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305153D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
ES2584183T3 (es) * 2003-03-28 2016-09-26 Ares Trading S.A. Formulaciones de cladribina para suministro mejorado oral y transmucosa
PL1608344T3 (pl) * 2003-03-28 2011-01-31 Ares Trading Sa Doustne formulacje kladrybiny
UA81305C2 (en) 2003-07-02 2007-12-25 Ares Trading Sa Formulation of cladribine (variants), cladribine-cyclodextrin complex, use of cladribine-cyclodextrin complex, mixture
EP1650192A4 (en) * 2003-07-24 2007-03-21 Astellas Pharma Inc QUINOLONE DERIVATIVE OR SALT THEREOF
US20070167353A1 (en) * 2003-10-24 2007-07-19 John Hilfinger Prodrug composition
JP2007517019A (ja) * 2003-12-29 2007-06-28 カン−フィテ・バイオファーマ・リミテッド 多発性硬化症の治療方法
US20080089892A1 (en) 2004-01-12 2008-04-17 Eli Lilly And Co. Fc Region Variants
US20050277615A1 (en) * 2004-05-17 2005-12-15 Can-Fite Biopharma Ltd. Pharmaceutical compositions having anti-inflammatory activity
CA3087419C (en) 2004-12-22 2023-03-07 Merck Serono S.A. Cladribine regimen for treating multiple sclerosis
PL1835922T3 (pl) * 2004-12-22 2009-10-30 Merck Serono Sa Terapia skojarzona stwardnienia rozsianego
CA2595126A1 (en) * 2005-01-14 2006-07-20 The Regents Of The University Of California Methods and compositions for preventing and treating a disease related to glycan dysregulation
WO2007135172A2 (en) 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis
US8126690B2 (en) * 2007-05-18 2012-02-28 The Regents Of The University Of Michigan Algorithms to predict clinical response, adherence, and shunting with thiopurines
EP2030615A3 (en) * 2007-08-13 2009-12-02 ELFORD, Howard L. Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
US8845627B2 (en) 2008-08-22 2014-09-30 Boston Scientific Scimed, Inc. Regulating pressure to lower temperature in a cryotherapy balloon catheter
WO2010042933A2 (en) 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
WO2012022740A1 (en) 2010-08-18 2012-02-23 Merck Serono S.A. Combination treatment of multiple sclerosis
CN105264127B (zh) 2013-03-15 2019-04-09 Gpb科学有限责任公司 颗粒的片上微流体处理
US10324011B2 (en) 2013-03-15 2019-06-18 The Trustees Of Princeton University Methods and devices for high throughput purification
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
US9839625B2 (en) 2014-11-06 2017-12-12 Northwestern University Inhibition of cancer cell motility
EP3341893A4 (en) * 2015-08-24 2019-03-06 GPB Scientific, LLC METHODS AND DEVICES FOR PURIFICATION AND CONCENTRATION OF MULTI-STEP CELLS
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
GB2564717A (en) 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
JP2021504363A (ja) 2017-11-24 2021-02-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 進行型多発性硬化症の処置における使用のためのクラドリビン処方計画
BR112023003432A2 (pt) 2020-09-10 2023-03-21 Merck Patent Gmbh Regime de tratamento para o tratamento de doenças autoimunes
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease
WO2022184867A1 (en) 2021-03-03 2022-09-09 Merck Patent Gmbh Improved treatment methods using dmds for the treatment of autoimmune diseases, and biomarker for predicting and/or optimising said treatment methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1572068C3 (de) * 1966-03-12 1976-01-08 Hoechst Ag, 6000 Frankfurt Lichtempfindliche Schicht zur Herstellung von Druckformen
US3472838A (en) * 1967-12-01 1969-10-14 Parke Davis & Co 9 - (beta - d - arabinofuranosyl) - 6 - (amidino) purine compounds and methods for their production
US4826823A (en) * 1985-02-05 1989-05-02 Warner-Lambert Company Methods of using 2-chloro-2'-deoxyadenosine-5'-phosphate and its salts
US4751221A (en) * 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
GB8708050D0 (en) * 1987-04-03 1987-05-07 Wellcome Found Therapeutic nucleosides
EP0314011A3 (de) * 1987-10-30 1990-04-11 F. Hoffmann-La Roche Ag Purinderivate
GB8725466D0 (en) 1987-10-30 1987-12-02 Hoffmann La Roche Purine derivatives
US4968702A (en) * 1989-01-17 1990-11-06 American Cyanamid Company Substituted quinolinecarboxylic acids

Also Published As

Publication number Publication date
RU2130308C1 (ru) 1999-05-20
BR9305907A (pt) 1997-10-21
DE69328474D1 (de) 2000-05-31
US5506214A (en) 1996-04-09
NO20000762L (no) 1994-09-13
RU94038043A (ru) 1996-11-20
NO942765L (no) 1994-09-13
NO309025B1 (no) 2000-12-04
JP2688113B2 (ja) 1997-12-08
HU218656B (hu) 2000-10-28
US5506213A (en) 1996-04-09
US5310732A (en) 1994-05-10
NO322328B1 (no) 2006-09-18
AU3724993A (en) 1993-09-13
JPH07507540A (ja) 1995-08-24
CH684310A5 (de) 1994-08-31
CA2130275A1 (en) 1993-09-02
EP0626853B1 (en) 2000-04-26
DE69328474T2 (de) 2000-09-28
EP0626853A1 (en) 1994-12-07
CA2130275C (en) 1999-06-29
FI943805A0 (fi) 1994-08-18
HU9402392D0 (en) 1994-10-28
WO1993016706A1 (en) 1993-09-02
ATE192045T1 (de) 2000-05-15
AU682818B2 (en) 1997-10-23
US5541164A (en) 1996-07-30
FI943805A (fi) 1994-10-19
HUT68030A (en) 1995-05-29
DK0626853T3 (da) 2000-08-07
NO942765D0 (no) 1994-07-25

Similar Documents

Publication Publication Date Title
NO20000762D0 (no) Anvendelse av substituerte adeninderivater til behandling av multippel sklerose
DE69630214D1 (de) Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
DE69333109D1 (de) Therapeutische nukleoside
IL128062A0 (en) Bicyclic pyrimidine derivatives and pharmaceutical compositions containing the same
FI941022A0 (fi) Spirosykliset piperidiinijohdannaiset
DE69109125D1 (de) Ringverknüpfte analoge von stickstoffenthaltenden nichtaromatischen heterocyclen.
DK0636025T3 (da) Forbindelser, der er egnede til behandling af allergiske og inflammatoriske sygdomme
ES2193252T3 (es) Quinolonas y su uso terapeutico.
MY111201A (en) New imidazopyridines
KR900700495A (ko) 치료제로서 유용한 치환된 아데닌 유도체
MY117381A (en) Use of 1-hydroxy-2-pyridone for the treatment of seborrheic dermatitis
ES2058191T3 (es) Acidos 2-fenil-4-quinolincarboxilicos substituidos.
NO180334C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive difluorstatonanaloger
ES2139669T3 (es) Nuevos derivados triciclicos de indan-2-mercaptoacetilamida 2-substituidos utiles como inhibidores de la encefalinasa.
YU13499A (sh) Primena 1-hidroksi-2-piridona za lečenje seboroitičnog dermatitisa
NO913331L (no) 4-substituerte dihydropyrido(4,3-d)pyrimidiner for behandling av hudforstyrrelser.
KR950700684A (ko) 시클릭 항-종양 촉진제 화합물, 그의 조성물, 제조 방법 및 용도(Cyclic Anti-Tumor Promoter Compounds, Compositions and Methods for Production and Use)
SE8107468L (sv) Komposition for behandling av psoriasis pa basis av en 1,8-dihydroxi-9-antron substituerad i 10-stellningen
DK0633776T3 (da) Forbindelser, som kan anvendes til behandling af allergiske og inflammatoriske sygdomme
DE69418050D1 (de) Antivirale analoge von difluorostaton
ES2173634T3 (es) Compuestos heterociclicos que presentan actividad inhibidora de mmp y tnf.

Legal Events

Date Code Title Description
MK1K Patent expired